| Non-Small Cell Lung Carcinoma
Cyramza vs Tafinlar + Mekinist
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Cyramza vs Tafinlar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTafinlar has a higher rate of injection site reactions vs Cyramza based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tafinlar but not Cyramza, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cyramza
Tafinlar
At A Glance
IV infusion
Every 2 weeks
VEGFR2 antagonist
Oral
Twice daily
BRAF kinase inhibitor
Indications
- Gastric Adenocarcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
- Liver carcinoma
- melanoma
- Non-Small Cell Lung Carcinoma
- Anaplastic thyroid carcinoma
- Low grade glioma
- Solid Neoplasm
Dosing
Gastric Adenocarcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent or in combination with weekly paclitaxel.
Non-Small Cell Lung Carcinoma (EGFR exon 19/21, first-line) 10 mg/kg every 2 weeks by IV infusion in combination with erlotinib.
Non-Small Cell Lung Carcinoma (post-platinum progression) 10 mg/kg by IV infusion on Day 1 of a 21-day cycle in combination with docetaxel.
Metastasis from malignant neoplasm of colon and/or rectum 8 mg/kg every 2 weeks by IV infusion prior to FOLFIRI.
Liver carcinoma 8 mg/kg every 2 weeks by IV infusion as a single agent.
Melanoma 150 mg orally twice daily as single agent or in combination with trametinib 2 mg once daily, oral route.
Non-Small Cell Lung Carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Anaplastic thyroid carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Low grade glioma Weight-based dosing in pediatric patients (20-150 mg twice daily) in combination with trametinib, oral route.
Solid Neoplasm 150 mg orally twice daily in combination with trametinib 2 mg once daily in adults; weight-based dosing in pediatric patients >= 1 year, oral route.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Hypertension, fatigue/asthenia, neutropenia, diarrhea, epistaxis, peripheral edema, stomatitis, proteinuria, thrombocytopenia, decreased appetite, nausea.
Serious Febrile neutropenia, pneumonia, hemorrhage, gastrointestinal perforation, arterial thromboembolic events, impaired wound healing, posterior reversible encephalopathy syndrome, proteinuria including nephrotic syndrome, infusion-related reactions, sepsis.
Postmarketing Thrombotic microangiopathy, hemangioma, dysphonia, arterial aneurysms/dissections/rupture, heart failure.
Most common (>= 20%) Pyrexia, rash, hyperkeratosis, headache, arthralgia, papilloma, alopecia, palmar-plantar erythrodysesthesia syndrome, chills, cough, nausea, vomiting, diarrhea, fatigue, dry skin, myalgia, constipation, decreased appetite, edema, hemorrhage, dyspnea, musculoskeletal pain, abdominal pain, epistaxis, dermatitis acneiform
Serious New primary malignancies (cutaneous and non-cutaneous RAS mutation-positive), hemorrhage, cardiomyopathy, uveitis, serious febrile reactions, serious skin toxicities including SCAR, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency, hemophagocytic lymphohistiocytosis
Pharmacology
Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D, inhibiting ligand-stimulated activation of VEGFR2 and thereby inhibiting endothelial cell proliferation, migration, and angiogenesis.
Dabrafenib is a BRAF kinase inhibitor that targets mutated BRAF V600E, V600K, and V600D enzymes, inhibiting cell growth in BRAF V600 mutation-positive tumors.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cyramza
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
Tafinlar
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Cyramza
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tafinlar
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Cyramza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Tafinlar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cyramza.
No savings programs available for Tafinlar.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CyramzaView full Cyramza profile
TafinlarView full Tafinlar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.